相关实验视频

Updated: Jun 18, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

左捆支部区域步调与心力衰竭需要心脏再同步治疗的患者的双心管步调相比的临床结果:系统性审查和元分析

Georgios Leventopoulos¹, Christoforos K Travlos¹, Virginia Anagnostopoulou¹

¹Department of Cardiology, General University Hospital of Patras, 26504 Patras, Greece.

Reviews in cardiovascular medicine

|July 30, 2024

概括

与双心室节奏 (BVP) 相比,用于心脏再同步治疗 (CRT) 的左捆支部区域节奏 (LBBAP) 显著降低了死亡率和心力衰竭住院治疗. LBBAP-CRT还导致心力衰竭症状和功能类的更大改善.

科学领域:

心脏病学心脏病学
电力生理学电力生理学
心脏衰竭管理的管理

背景情况:

双管节拍 (BVP) 是心力衰竭 (HF) 患者的心脏再同步疗法 (CRT) 的标准治疗方法.
左捆支部区域节奏 (LBBAP) 是一种旨在改善心脏同步的新兴策略.

研究的目的:

系统地审查和分析临床结果,将LBBAP-CRT与BVP-CRT进行比较.
评估LBBAP-CRT在降低HF患者的死亡率,住院和改善HF患者的功能类别方面的疗效.

主要方法:

在Medline,Embase,Cochrane和Web of Science搜索了LBBAP-CRT和BVP-CRT的比较研究.
包括RCT和对HF患者的观察性研究,LVEF<40%和显著的节奏需求.
使用元分析和偏差风险工具评估了全因死亡率,心力衰竭住院 (HFH) 和NYHA类改进.

主要成果:

分析了11项涉及3141名患者的研究.
与BVP-CRT相比,LBBAP-CRT显示所有原因死亡风险降低 (RR:0.71).
与BVP-CRT相比,LBBAP-CRT显著降低了HFH风险 (RR:0.59) 并改善了NYHA类 (WMD: -0.36).

结论:

与心力衰竭患者的BVP-CRT相比,LBBAP-CRT与更好的临床结果有关.
在减少死亡率和住院治疗方面,LBBAP-CRT提供了潜在的优势.
这一元分析支持LBBAP-CRT作为心脏再同步治疗的有效替代方案.

关键词:

左捆分支机构地区节奏节奏.这是一个元分析.重新同步重新同步的时间.

更多相关视频

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

相关概念视频

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...